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thrombocytopenia, and many others, among the different
ethnic groups.
Thus there exist in South Africa abundant and excel-
lent opportunities for comparative studies of disease pat-
terns. While Council does not attempt to direct the work
of the researchers or to dictate what should be done, it is
fundamental to the policy of the MRC to encourage and
support medical research that can best be done in this
country, ensuring that investigations in depth are under-
taken by experienced scientists with all the sophisticated
facilities that are available.
In South Africa we find close to each other highly
sophisticated facilities, well-trained scientists and circum-
stances in which great ethnical and geographical differ-
ences can be observed in diseases. This creates superb
possibilities for comparative studies of disease patterns.
These studies can be investigated in depth at laboratory
level. Furthermore, South Africa is richly endowed with a
large variety of animals and in particular with subhuman
primates. These factors create a great potential for clinical
and experimental research.
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Mithramycin •In Paget's Disease
S. EPSTEIN
SUMMARY
Mithramycin, a cytotoxic agent, has been used to treat
6 patients with severe symptomatic Paget's disease of
bone. Bone pain improved dramatically. Side-effects in-
cluded hypocalcaemia and nausea, but were not serious.
Mithramycin is valuable in selected cases of Paget's
disease.
S. Afr. Med. l., 48, 1328 (1974).
Paget's disease (osteitis deformans) is a relatively common
disorder of bone, affecting 11 % of persons over the age
of 80 years in certain countries.' The majority of cases
are asymptomatic but the occurrence of severe bone pain,
progressive deformity, pathological fractures and sarco-
matous changes, necessitates treatment. Until recently
treatment has been largely limited to analgesics with little
regard to the correction of the underlying defects, which
include excessive osteoclastic activity destroying normal
bone.
Mithramycin, a cytotoxic agent derived from an actino-
mycete of the Streptomyces genus, inhibits DNA and
RNA synthesis as well as skeletal metabolism. It was
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originally successfully used in the treatment of testicular
tumours' and hypercalcaemic states: It was then shown
to improve the clinical and biochemical features of
Paget's disease, probably by inhibition of osteoclasts!
We have encountered 6 patients with gross, widespread
Paget's disease with severe bone pain, in whom we
decided to observe the effects of mithramycin. The study
was not double-blind and did not include comparison with
other therapy.
PATIENTS AND METHODS
Six patients were admitted to Groote Schuur Hospital
suffering from severe· bone pain with radiologically,
clinically and biochemically proved osteitis deformans.
This pain in each case was sufficient to disrupt the patient's
daily life, and prevent sleeping and having full mobility.
It was only partially and temporarily relieved by previous
therapeutic attempts in 5 of the 6 patients (patient 5 had
not been administered any therapy). There was no asso-
ciated hepatic, haematological or renal abnormality as
determined on the 12/60 AutoAnalyzer and Coulter
counter. Mithramycin (kindly supplied by courtesy of
Pfizer Pharmaceuticals), was administered intravenously
in a dose of 15 pg/kg body mass over 4 hours in 1 litre
of '5% dextrose water solution. This dose was given daily
as a course for 5 days. Further courses were given only
if the patient failed to improve on the first course. No
patient received more than 3 courses. The patients were
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seen daily during their hospital stay, one month after
discharge and then every 3 months as far as possible.
Two patients, Nos. 4 and 6, were seen only twice after dis-
charge as they had been referred from distant hospitals. At
each visit a repeat 12/60 'auto-analysis' was performed.
During each course of therapy, daily measurement of
serum prothrombin. platelets, liver enzymes, creatinine,
calcium, phosphorus and alkaline phosphatase were deter-
mined.
Where possible urinary calcium and hydroxyproline
were measured. A rise in serum creatinine, liver enzymes,
bilirubin, and a fall in platelets, white cells or prothrombin
index would have been considered indications for ~topping
therapy.
RESULTS
The symptomatology, radiological involvement and
previous medication of each patient is shown in Table J.
All 6 patients experienced a reduction ef pain (Table ITI),
and in 3 this was dramatic. Mobility was improved in
2 patients (Table Ill), 1 of whom could discard the use
of a wheelchair (patient 2). The failure to restore mobility
in the others was probably related to secondary osleo-
arthritic changes of the neighbouring joints.
Side-effects (Table Ill) were limited to nausea. In 1
patient this was so severe th:lt despite anti-emetics, therapy
had to be discontinued. In patient 6 (fable ill) pain was.
however, dramatically relieved after 3 days of treatment.
In the other 5 patients nausea was transient and mild.
The biochemical changes were less striking than the
improvement in pain. In all patients the alkaline phos-
phatase decreased during follow-up (Table IV). Except in
patient 4, this fall was not sustained, and at the end of
3 months the alkaline phosphatase had returned to pre-
treatment values (Table 11). A drop in serum calcium
occurred in every patient, the lowest value (not shown
on Table) being 6,9 mg/loo m!. At no stage did patients
manifest tetany or paraesthesia. This asymptomatic
hypocalcaemia was self-limiting, and 1 month after treat-
ment 4 patients were normocalcaemic (9 - 11 mg/loo ml).






























Headache; pain In legs





Pelvis, left femur, lumbar
spine, skull, osteo-
arthritis of left hip
Skull, left side of pelvis,
including hip, lumbar
spine
Skull, pelvis, right and
left femora, right
humerus
Skull, pelvis, right and
left femora, lower
dorsal vertebrae
Right pelVis, right femoral
head, upper 2/3 left
tibia, uper 2/3 right
humerus
Skull, lumbar spine, right
















TABLE 11. PRETREATMENT BIOCHEMISTRY OF PATIENTS WITH PAGET'S DISEASE
Alkaline Serum Serum Urinary
phosphatase calcium phosphorus calcium Urinary
(N=14 -85 (N=9-11 (N=2.S-4.S (N=± 240 hydroxyprolir.e
Patients tU) mg/100 ml) mg/l00 ml) mg/24 h) (N=<SO mg mg/24 11)
1 722 10,0 3,8 330
2 >700 9,1 3,1 302
3 >700 9,7 4,4 125 168
4 562 10,5 3,7 280
5 29' 9,7 3,3 240 59,1
8 >700 9,4 3,6 '27
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TABLE Ill. POST-TREATMENT OBSERVATIONS OF PATIENTS WITH PAGET'S DISEASE
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Patient Pain Mobility Side-effects
Improved Still impaired as severe Nil
osteo-a rthritis of right
hip
2 Much improved Walked without difficulty Nausea on day 1 of administration
3 Much improved Improved Nausea on day 1 of administration
4 Improved No improvement Nausea on day 4 of administration
5 Improved No improvement Nil
6 Much improved Had no limitation origi- Severe nausea-necessitating termi·
nally nation of therapy after 3 days
TABLE IV. POST-TREATMENT BIOCHEMISTRY OF PATIENTS WITH PAGET'S DISEASE
Serum phosphorus Urinary
Alkaline phosphatase Serum calcium eN = 2,5 - 4,5 Urinary calcium hydroxyproline
eN = 14 - 85 IU) eN = 9 - 11 mg/100 ml) mg/100 ml) eN = -+-240 mg/24 h) eN = <50 mg/24 h)
Patient 5 days! 1/12t 3/12t 5 days 1/12 3/12 5 days 1/12 3/12 5 days 1/12 3/12 5 days 1/12 3/12
1* 713 554 >700 8,8 8,0 9,5 3,0 2,9 3,9 213
2 >700 320 >700 8,6 10,1 9,5 3,9 3,4 3,4 80
3* 417 512 691 10,5 8,1 10,2 4,5 2,4 4,1 35 39 105
4 422 256 375 7,2 9,5 9,4 2,4 3,4 4,5 160 97,5
5 268 326 373 8,9 10,1 9,9 3,2 4,2 4,1 128
6 >700 482 >700 9,3 10,1 9,4 2,4 3,1 3,6 12,7 151
'" More than 1 course. t 5 days postinfusion. * 1/12 = 1 month postinfusion; 3/12 = 3 months postinfusion.
At the end of the 3 months all were normocalcaemic
(Table IV). Urinary hydroxyproline was estimated in only
3 patients, and showed a decrease in 2 at some stage
during the study. Urinary calcium excretion fell in 4
patients after 5 days' treatment (Table IV). No changes
in hepatic and renal function or in blood count were
observed.
DISCUSSION
The most striking benefit derived from the use of
mithramycin in Paget's disease was the relief of bone pain,
and to a lesser extent, return of mobility. Other workers
have shown a decrease in the various indices of bone
turnover, e.g. hydroxyprolinuria and serum alkaline phos-
phatase, to normal or near normal values while on
treatment and for a limited period thereafter. X-ray films
of the affected bone have also shown improvement:
In our study alkaline phosphatase decreased transiently
but rose to pretreatment levels soon after stopping therapy.
That this faIl in alkaline phosphatase was so brief may
have been due to the relatively short course that was
given to each patient. Perhaps prolonged low-dose mithra-
mycin on an outpatient basis is required to restore
normality of bone turnover; such a scheme is being
investigated elsewhere: We observed a considerable,
though transient, fall in serum calcium levels. This hypo-
calcaemic property of mithramycin has been used to
treat resistant hypercalcaemia.'
Other agents used in the treatment· of Paget's disease
include thyrocalcitonin (TCT),< and the diphosphonates:
Thyrocalcitonin, which inhibits bone resorption, is expen-
sive and requires prolonged treatment with daily or weekly
intramuscular injections. The development of neutralisin.'5
antibodies to porcine or salmon thyrocalcitonin has also
handicapped the therapeutic benefit of this hormone.
Human TCf is not commercially available but appears
promising in this condition, and Woodhouse et af.' have
observed progressive symptomatic and radiological im-
provement from its use. Disodium editronate (EHDP), a
diphosphonate, slows bone turnover rate in experimental
animals, and has been used in Paget's disease to reduce
the excessive resorption and remodelling of bone. How-
ever, impaired mineralisation of osteoid tissue in normal
and diseased bone has been seen with this compound; and
the effect of smaller doses is still being investigated.'
We suggest that mithramycin be used in selected cases
of Paget's disease, provided bone pain is the major
symptom and no contra-indications to its use are present.
The hypocalcaemic side~effect of this drug may also be
beneficially employed as an emergency therapy in resis-
tant life-threatening hypercalcaemic situations.
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